Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thymus Neoplasms 1 Ovarian Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma 1 Lung Neoplasms 1 Hernia, Hiatal 1 Gastroesophageal Reflux 1 Esophageal Neoplasms 1 Esophageal Diseases 1 Esophageal Achalasia 1 Craniopharyngioma 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Cancer Female 1 Adenocarcinoma 1

Interventions

pembrolizumab 105 Specimen Handling 55 Magnetic Resonance Spectroscopy 48 Biopsy 47 Nivolumab 40 Paclitaxel 35 Gemcitabine 30 Radiosurgery 29 Carboplatin 28 Irinotecan 22 Ipilimumab 22 Cyclophosphamide 22 Cisplatin 22 trastuzumab deruxtecan 21 Leucovorin 19 Capecitabine 19 Fluorouracil 18 Cetuximab 18 Bevacizumab 18 130-nm albumin-bound paclitaxel 18 Pemetrexed 17 Fulvestrant 17 Drug Therapy 16 Docetaxel 16 Taxes 15 Oxaliplatin 15 olaparib 14 abemaciclib 14 Radiotherapy 14 palbociclib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × Tumor Burden × 1 year × Clear all

NCT04257162 2025-09-09

HER2-PREDICT

SOLTI Breast Cancer Research Group

Phase NA Active not recruiting

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡